Uniqure NV (NASDAQ:QURE) VP Alexander Edward Kuta III Sells 4,000 Shares

Uniqure NV (NASDAQ:QURE) VP Alexander Edward Kuta III sold 4,000 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $52.08, for a total transaction of $208,320.00. Following the completion of the sale, the vice president now owns 45,578 shares of the company’s stock, valued at approximately $2,373,702.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Alexander Edward Kuta III also recently made the following trade(s):

  • On Tuesday, October 15th, Alexander Edward Kuta III sold 4,000 shares of Uniqure stock. The shares were sold at an average price of $42.35, for a total transaction of $169,400.00.
  • On Monday, September 16th, Alexander Edward Kuta III sold 4,000 shares of Uniqure stock. The shares were sold at an average price of $47.26, for a total transaction of $189,040.00.

Shares of Uniqure stock traded down $0.59 on Wednesday, reaching $54.40. The stock had a trading volume of 3,178 shares, compared to its average volume of 435,255. The company has a 50 day moving average price of $46.98 and a 200 day moving average price of $57.95. The company has a quick ratio of 14.33, a current ratio of 14.33 and a debt-to-equity ratio of 0.19. Uniqure NV has a 1 year low of $24.07 and a 1 year high of $82.49. The stock has a market capitalization of $2.31 billion, a P/E ratio of -23.25 and a beta of 0.84.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, October 28th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.23. Uniqure had a negative net margin of 1,670.86% and a negative return on equity of 51.12%. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.24 million. On average, analysts forecast that Uniqure NV will post -3 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on QURE shares. Guggenheim lowered shares of Uniqure from a “buy” rating to a “neutral” rating in a report on Monday, July 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Uniqure in a report on Thursday, October 17th. Sanford C. Bernstein started coverage on shares of Uniqure in a report on Tuesday, September 24th. They issued an “outperform” rating and a $73.00 price target for the company. Mizuho started coverage on shares of Uniqure in a report on Thursday, September 12th. They issued a “buy” rating and a $67.00 price target for the company. Finally, Credit Suisse Group started coverage on shares of Uniqure in a report on Tuesday, November 5th. They issued an “outperform” rating and a $76.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Uniqure has a consensus rating of “Buy” and an average target price of $74.43.

Institutional investors have recently modified their holdings of the company. Griffin Asset Management Inc. purchased a new stake in Uniqure during the 2nd quarter worth approximately $39,000. US Bancorp DE grew its position in Uniqure by 275.5% during the 2nd quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 427 shares during the last quarter. Botty Investors LLC purchased a new stake in Uniqure during the 2nd quarter worth approximately $78,000. Rockefeller Capital Management L.P. purchased a new stake in Uniqure during the 2nd quarter worth approximately $78,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Uniqure by 21.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,975 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 346 shares during the last quarter. 63.71% of the stock is currently owned by hedge funds and other institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: Market Indexes

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.